| BSE: 532150 | Sector: Health care |
| NSE: INDRAMEDCO | ISIN Code: INE681B01017 |
| BSE 00:00 | 17 Sep | 36.80 |
-0.30 (-0.81%) |
OPEN
37.15 |
HIGH
37.50 |
LOW
36.60 |
| NSE 00:00 | 17 Sep | 36.70 |
-0.50 (-1.34%) |
OPEN
37.35 |
HIGH
37.55 |
LOW
36.65 |
| OPEN | 37.15 |
| PREVIOUS CLOSE | 37.10 |
| VOLUME | 4094 |
| 52-Week high | 46.00 |
| 52-Week low | 35.00 |
| P/E | 11.08 |
| Mkt Cap.(Rs cr) | 337 |
| Buy Price | 36.10 |
| Buy Qty | 200.00 |
| Sell Price | 36.80 |
| Sell Qty | 200.00 |
3.56 pm | 17 Sep 2019 | Business Standard
All that happened in markets today
11.20 am | 17 Sep 2019 | Business Standard
On August 9, CARE Ratings upgraded the ratings of VOL's bank facilities with stable outlook
11.50 pm | 16 Sep 2019 | Business Standard
Front end of the business to go to a separate firm, which will focus on achieving Rs 10,000 cr revenue and 30% ROCE within 5 years
4.23 pm | 13 Sep 2019 | Business Standard
All that happened in markets today.
4.23 pm | 13 Sep 2019 | Business Standard
All that happened in markets today.
9.01 am | 13 Sep 2019 | Business Standard
Here's a look at the top stocks that may remain in focus today.
9.01 am | 13 Sep 2019 | Business Standard
Here's a look at the top stocks that may remain in focus today.
8.12 am | 13 Sep 2019 | Business Standard
Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor
11.45 pm | 12 Sep 2019 | Business Standard
Dr Reddy's, Lupin, Sun Pharma and Cadila Healthcare outperformed the local industry growth in recent months, a trend expected to continue
4.04 pm | 12 Sep 2019 | Business Standard
All that happened in markets today.
4.04 pm | 12 Sep 2019 | Business Standard
All that happened in markets today.
10.00 am | 12 Sep 2019 | Business Standard
The aim of the stake sale is to reduce the promoters' pledged shares in the company.
9.00 am | 12 Sep 2019 | Business Standard
Here's a list of counters that may hog the limelight today -
1.05 am | 12 Sep 2019 | Business Standard
Fortis Hospitals Ltd, which has not been under this list, holds around 62 per cent shares in the company, till the end of June, this year
12.43 am | 12 Sep 2019 | Business Standard
A combination of foreign and domestic institutional investors are expected to participate
10.40 pm | 11 Sep 2019 | Business Standard
Restructuring and consumer acquisition to be key drivers of revenue
8.20 pm | 11 Sep 2019 | Business Standard
The sale will translate into average annual revenue loss of Rs 470 cr, which Sanofi plans to mitigate through renewed focus on core activities and bra...
4.05 pm | 11 Sep 2019 | Business Standard
All that happened in the markets today
12.25 am | 9 Sep 2019 | Business Standard
Lupin, the largest player in India's anti-TB market, too admitted that in anti-TB segment, the focus on branded business has declined in the past few ...
11.39 pm | 8 Sep 2019 | Business Standard
Company officials said the private label business was 6.5 per cent of revenue last year and expected to be 7 per cent this year
